[go: up one dir, main page]

AU2001272849A1 - Composition for the treatment of osteoarthritis - Google Patents

Composition for the treatment of osteoarthritis

Info

Publication number
AU2001272849A1
AU2001272849A1 AU2001272849A AU7284901A AU2001272849A1 AU 2001272849 A1 AU2001272849 A1 AU 2001272849A1 AU 2001272849 A AU2001272849 A AU 2001272849A AU 7284901 A AU7284901 A AU 7284901A AU 2001272849 A1 AU2001272849 A1 AU 2001272849A1
Authority
AU
Australia
Prior art keywords
osteoarthritis
treatment
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001272849A
Inventor
Ivo Maria Franciscus Graus
Hobbe Friso Smit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutricia NV
Original Assignee
Nutricia NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutricia NV filed Critical Nutricia NV
Publication of AU2001272849A1 publication Critical patent/AU2001272849A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2001272849A 2000-07-10 2001-07-10 Composition for the treatment of osteoarthritis Abandoned AU2001272849A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61356200A 2000-07-10 2000-07-10
US09/613,562 2000-07-10
PCT/NL2001/000525 WO2002004003A2 (en) 2000-07-10 2001-07-10 Composition for the treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
AU2001272849A1 true AU2001272849A1 (en) 2002-01-21

Family

ID=24457782

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001272849A Abandoned AU2001272849A1 (en) 2000-07-10 2001-07-10 Composition for the treatment of osteoarthritis

Country Status (4)

Country Link
US (1) US6492429B1 (en)
EP (1) EP1347766A2 (en)
AU (1) AU2001272849A1 (en)
WO (1) WO2002004003A2 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US6534086B1 (en) * 2000-03-06 2003-03-18 Metagenics, Inc. Composition and method for treatment of inflammation and pain in mammals
GB2368012A (en) * 2000-10-19 2002-04-24 Nicholas John Larkins Preparation for the relief of inflammatory disease
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US20040115290A1 (en) * 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US8206753B2 (en) 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US7901714B2 (en) 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US8168234B2 (en) 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US8142819B2 (en) 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US7901713B2 (en) 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
WO2003002125A2 (en) * 2001-06-29 2003-01-09 Astion A/S Combination of aminosugars and cysteine or cysteine derivatives
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
US6949586B2 (en) * 2002-02-11 2005-09-27 Council Of Scientific Research Synergistic composition of trans-tetracos-15-enoic acid and Apocynin and method of treatment for hepatotoxicity
WO2003077860A2 (en) * 2002-03-13 2003-09-25 Biophysica, Inc. BOSWELLIN COMPOSITIONS ENHANCED WITH 3-β-ACETYL-11-KETO-β-BOSWELLIC ACID (“AKBA”), INDUSTRIAL MANUFACTURE AND THEIR USES
ATE348648T1 (en) * 2002-03-25 2007-01-15 Council Scient Ind Res SYNERGISTIC COMPOSITION OF TRANS-TETRACOS-15-ENENE ACID AND APOCYNINE, AND USE THEREOF
GB0209254D0 (en) * 2002-04-23 2002-06-05 Larkins Nicholas J Preparation for the relief of disease
AU2003286549B2 (en) 2002-10-21 2006-11-30 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7018663B2 (en) 2002-11-21 2006-03-28 Donald E. Scott Application of dried nettle to the skin
CA2517416A1 (en) * 2003-02-28 2004-09-10 Howard Florey Institute Of Experimental Physiology And Medicine Therapeutic compositions
US8703209B2 (en) * 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
EP1502594A1 (en) * 2003-07-31 2005-02-02 Pynogin GmbH A health care composition for decreasing the risk of thrombosis including a mixture of proanthocyanidins and sesquiterpenes
US7758903B2 (en) 2003-09-12 2010-07-20 Access Business Group International Llc Cytokine modulators and related methods of use
KR101245440B1 (en) * 2003-09-12 2013-03-19 액세스 비지니스 그룹 인터내셔날 엘엘씨 Cytokine modulators and related method of use
US7758902B2 (en) * 2003-09-12 2010-07-20 Access Business Group International Llc Cytokine modulators and related methods of use
US20090169585A1 (en) * 2003-10-23 2009-07-02 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
WO2005110431A1 (en) * 2004-05-19 2005-11-24 University Of Manitoba Herbal product containing glucosamine
US7455860B2 (en) * 2004-08-11 2008-11-25 Laila Nutraceuticals Dietary supplement formulation for controlling inflammation and cancer
ITRM20040439A1 (en) * 2004-09-16 2004-12-16 Ca Di Group S R L PRODUCT WITH SELECTIVE ANTI-INFLAMMATORY ACTION AND ACTION AGAINST TISSUE FIBROGENESIS.
US20060246115A1 (en) * 2005-03-04 2006-11-02 Ricardo Rueda Nutritional products for ameliorating symptoms of rheumatoid arthritis
GB2424833B (en) * 2005-04-08 2008-12-10 Nicholas John Larkins Anti-inflammatory formulation comprising apocyanin and paeonol
US7956031B2 (en) * 2005-05-31 2011-06-07 Naidu Lp Metallo-lactoferrin-coenzyme compositions for trigger and release of bioenergy
EP2248532A1 (en) 2005-08-09 2010-11-10 Metaproteomics, LLP Protein kinase modulation by hops and acacia products cross-reference to related applications
US20070071809A1 (en) * 2005-09-26 2007-03-29 Vad Vijay B Ginger containing compositions to control pain
US20070265350A1 (en) * 2005-12-30 2007-11-15 University Of Iowa Research Foundation Method of identifying compounds useful to treat neuronal degenerative diseases
GB2436063A (en) * 2006-03-16 2007-09-19 Nicholas John Larkins Pharmaceutical composition for the treatment of excess mucous production
US8021659B2 (en) * 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
EP1925301A1 (en) * 2006-11-24 2008-05-28 DSMIP Assets B.V. Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders
WO2008083389A1 (en) * 2006-12-29 2008-07-10 Moleculin, L.L.C. Methods of treating skin disorders with caffeic acid analogs
EP2152684A4 (en) 2007-05-11 2011-05-18 Metaproteomics Llc METHODS AND COMPOSITIONS FOR DETOXIFICATION OF HEAVY METALS
GB2463080A (en) * 2008-09-02 2010-03-03 Nicholas John Larkins Pharmaceutical preparation
US8450337B2 (en) * 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
EP2723357A4 (en) 2011-06-21 2015-04-01 Bvw Holding Ag Medical device comprising boswellic acid
US8916528B2 (en) 2011-11-16 2014-12-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
CN104540513B (en) * 2012-01-16 2019-04-05 赫克托·德·杰休斯·维莱斯-里韦拉 Botanical compositions for treating pain associated with joint disease
WO2014138372A1 (en) * 2013-03-06 2014-09-12 Primavera Biosciences, Inc. Composition and method for treating osteoarthritis
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
CA2966487A1 (en) * 2014-11-06 2016-05-12 NWO Stem Cure, LLC Nutraceutical supplement with lactobacillus rhamnosus
US11702672B2 (en) 2016-02-08 2023-07-18 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
US11684679B2 (en) 2016-03-07 2023-06-27 University Of Iowa Research Foundation AAV-mediated expression using a synthetic promoter and enhancer
WO2017205739A1 (en) 2016-05-26 2017-11-30 University Of Iowa Research Foundation cis AND trans REQUIREMENTS FOR TERMINAL RESOLUTION OF HUMAN BOCAVIRUS 1
WO2018132747A1 (en) 2017-01-13 2018-07-19 University Of Iowa Research Foundation Bocaparvovirus small noncoding rna and uses thereof
EP4110396A1 (en) * 2020-02-26 2023-01-04 Universiteit Maastricht Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia
EP4140474A1 (en) * 2021-08-23 2023-03-01 Theracell Advanced Biotechnology S.A. Nutraceutical for the reduction of osteoarthritic pain and inflammation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2187327B1 (en) * 1972-06-15 1975-06-20 Rech Pharm Scientifiques
US4315028A (en) * 1978-12-22 1982-02-09 Scheinberg Israel H Method of treatment of rheumatoid arthritis
US5120538A (en) * 1990-02-05 1992-06-09 Pt Darya-Varia Laboratoria Combinations of compounds isolated from curcuma spp as anti-inflammatory agents
DE4137540A1 (en) 1991-11-14 1993-05-19 Steigerwald Arzneimittelwerk USE OF PREPARATIONS OF CURCUMA PLANTS
AU1846695A (en) 1994-02-16 1995-09-04 Idun Pharmaceuticals Methods for controlling free radical generation by inflammatory cells
US5494668A (en) 1994-07-11 1996-02-27 Patwardhan; Bhushan Method of treating musculoskeletal disease and a novel composition therefor
US5629351A (en) 1995-04-13 1997-05-13 Council Of Scientific & Industrial Research Boswellic acid compositions and preparation thereof
DE19531067A1 (en) 1995-08-23 1997-02-27 Hermann P T Prof Dr Med Ammon Use of boswellic acid and its derivatives for inhibiting normal and increased leukocyte elastase or plasmin activity
US5763496A (en) * 1995-11-27 1998-06-09 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
US5872124A (en) * 1996-07-31 1999-02-16 Thomas Jefferson University Treatment of diseases of the central nervous system using uric acid as a scavenger of peroxynitrite
US5888514A (en) * 1997-05-23 1999-03-30 Weisman; Bernard Natural composition for treating bone or joint inflammation

Also Published As

Publication number Publication date
US6492429B1 (en) 2002-12-10
EP1347766A2 (en) 2003-10-01
WO2002004003A3 (en) 2003-07-31
WO2002004003A2 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
AU2001272849A1 (en) Composition for the treatment of osteoarthritis
AU2001268659A1 (en) Water treatment compositions
AU2001272852A1 (en) Composition for the treatment of migraine
AU2935200A (en) Compounds for the treatment of obesity
AU2000276362A1 (en) Composition for the treatment of diabetes
AU2001233081A1 (en) Composition for treatment of stress
AU2000258650A1 (en) 2-piperidone compounds for the treatment of cancer
AU2001253749A1 (en) 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
AU2002346882A1 (en) Methods for the treatment of osteoarthritis and compositions thereof
AU2002365621A1 (en) Composition for treating the surface of the skin
AU2002329441A1 (en) Process for the preparation of 3 - isochromanone
AU2000231423A1 (en) Specific therapeutic composition for treating aids
AU2002358085A1 (en) Process for the preparation of 4-methyl-7-aminoquinolones
AU2683500A (en) Compositions for the treatment of pain
AU5462901A (en) Process for the preparation of (pyridinylidene)-phthalides
AU5416500A (en) Pharmaceutical composition for the treatment of calcification
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2000272704A1 (en) Use of compounds for the treatment of obesity
AU2002324291A1 (en) Process for the preparation of beta-ionylideneacetaldehyde
AU2000279379A1 (en) An improved process for the preparation of 10h-phenoxazine
AU2000258438A1 (en) An improved process for the preparation of acylferrocenes
AU2002221748A1 (en) Stain treatment composition
AU2000268609A1 (en) Intraarticular agent for the treatment of osteoarthritis
AU2001271524A1 (en) Process for the preparation of pentafluoroethane
AU2002231651A1 (en) Process for the preparation of morpholinones